Effectiveness of Thyroid Gland Size Determination by Ultrasound versus Manual Palpation in Success of Radioactive Iodine Treatment for Graves' Disease

Phase 3

Completed

• Conditions: Graves' disease; Ultrasonography; Radioactive iodine ablation; Thyrotropin

• Registration Number: TCTR20211109003
• Lead Sponsor: Routine to Research Unit (R2R), Faculty of Medicine Siriraj Hospital, Mahidol University

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Study Completion: 2021-10-07
• Study Start: 2021-11-09
• Last Update Posted: 19 August 2024

Recruitment & Eligibility

• Status: Completed
• Sex: All
• Target Recruitment: 123

Inclusion Criteria

1. Patients who were referred to Division of Nuclear Medicine, Faculty of Medicine Siriraj Hospital for the first radioactive iodine treatment for Graves' disease
2. Stop antithyroid drugs 5-7 days prior to administration of radioactive iodine

Exclusion Criteria

1. Previously treated with radioactive iodine treatment or thyroidectomy
2. Required a radioactive iodine dose of more than 150 microcuries per 1 gram of thyroid tissue
3. Pregnant or lactating women
4. Not voluntarily agree to participate in the study

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Success of radioactive iodine treatment for Graves' disease At 6 months after radioactive iodine treatment Ability to discontinue antithyroid drugs

Secondary Outcome Measures

Name	Time	Method
Factors associated with success of radioactive iodine treatment for Graves' disease At 6 months after radioactive iodine treatment Determination of factors associated with success of radioactive iodine treatment for Graves' disease